Navigation Links
Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
Date:3/16/2009

BRIDGEWATER, N.J., March 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that Paul Chew, M.D., has been appointed to Chief Science Officer/Chief Medical Officer, U.S., effective April 1. He was previously President, R&D, sanofi-aventis, U.S.

As the company's Chief Science Officer and Chief Medical Officer, Paul Chew will establish a unified medical voice for sanofi-aventis U.S. among internal and external stakeholders. He will be responsible for overseeing U.S. Medical Affairs in addition to his continued oversight of the U.S. R&D organization in coordination with the Group in Paris. Further, Paul Chew will be charged with representing accurate and timely clinical and safety information to health authorities, payers, patients and physicians that will foster safe and appropriate use of our products.

Paul Chew's primary reporting will be to Greg Irace, President and Chief Executive Officer, sanofi-aventis U.S., in addition to Marc Cluzel, Group Senior Vice President of R&D and Jean-Pierre Lehner, Group Chief Medical Officer.

"Paul brings deep, scientific expertise and proven leadership to both the R&D and Medical functions in the U.S. - a critical area in which the science and the business of our industry intersect," said Greg Irace. "In this new role, Paul will be in a position to bring greater scientific and product insights to our organization, greater clarity and dialogue with members of the healthcare system and, ultimately, greater value to patients in the form of improved health outcomes."

The new role of Chief Science Officer/Chief Medical Officer is part of the company's overall organizational drive to ensure all components of the U.S. affiliate work in a coordinated manner to achieve harmonized processes, cost-effectiveness and best practice sharing in the design, conduct and monitoring of clinical studies.

About sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

For more information, www.sanofi-aventis.us or www.sanofi-aventis.com

    Media Contact:

    Lisa Buffington
    908-981-6569
    Lisa.Buffington@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Jim Yong Kim Appointed 17th President of Dartmouth College
2. Industry Veterans Appointed to Key Leadership Posts at Healthcare Informatics Associates (HIA), an InfoLogix Company
3. Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
4. Brickson Diamond Appointed Board Chair of National Hospice Foundation
5. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
6. Margaret Laub Appointed to IntelliDOT Board of Directors
7. Laurence Debroux Appointed Chief Strategic Officer (CSO)
8. Jean-Pierre Lehner Appointed Chief Medical Officer
9. Alice Stollenwerk Petrulis, MD, FACP, Appointed to NQF Care Coordination Committee
10. Former Assistant Secretary for Aging, The Honorable Josefina G. Carbonell, Appointed Senior Vice President at Independent Living Systems
11. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, ... systems announces the issuance of United States Patent Number 9,695,398 (the '398 patent) ... technology. The '398 and '324 patents cover methods and systems for optimizing ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... in National Harbor, MD. This year's theme focuses on the new ISO/IEC 17025 ... for quality and integrity in testing and calibration will be changed. , ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... sleep management solution focused on delivering end-to-end sleep health care at scale, ... Recent literature shows that adherence rates for positive airway pressure (PAP) therapy, the ...
(Date:7/24/2017)... ... , ... A Southern California-based author has released a new book which details ... overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights the author’s ... , In “Memories,” readers get a firsthand look at what Michelle has been through ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating ... enrolled over 100,000 children in their treatment program. Clubfoot is a pervasive problem ... where treatment is limited or non-existent. Without intervention, these children are destined to ...
Breaking Medicine News(10 mins):
(Date:7/15/2017)... , July 15, 2017 Enterin Inc., a ... treat Parkinson,s disease (PD), today announced the completion of a ... investors New Ventures III, as well as the participation of ... absolutely thrilled to have the support of New Ventures III ... investors as validation of the potential of our platform technology ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/13/2017)... 13, 2017 RK Logistics Group, Inc. was awarded ... for its Fremont, CA headquarters facility ... Tri-Valley and San Jose for hi-tech, ... Fremont , with its Fremont Innovation District, is excited ... a powerful resource to the hundreds of biotech, pharma and ...
Breaking Medicine Technology: